Obesity

AdaptHealth Appoints Suzanne Foster as Chief Executive Officer

Retrieved on: 
Wednesday, April 17, 2024
Nursing, Medical Supplies, Health, Medical Devices, Practice Management, Managed Care, Cardiology, Health policy, Danaher Corporation, Chairperson, Cardinal Health, Diabetes, History, Obesity, JD, Sleep apnea, Suffolk University Law School, Stanley Black & Decker, Harvard University, Growth, Management

AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that its Board of Directors has named Suzanne Foster as its Chief Executive Officer.

Key Points: 
  • AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that its Board of Directors has named Suzanne Foster as its Chief Executive Officer.
  • Ms. Foster will assume leadership of the Company from interim CEO and Chairman of the Board, Richard Barasch, on May 20, 2024.
  • Ms. Foster holds an MPH in Law and Health Policy from Harvard University and a JD from Suffolk University Law School.
  • We are grateful for his dedication to AdaptHealth and know he is delivering a healthy business to Suzanne.

Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator

Retrieved on: 
Tuesday, April 16, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Cyclothymia, Major depressive disorder, Diabetes, Depression, Literature, Obesity, DNA, DSM-IV codes, Patient, MADRS, Gene expression, DNA repair, SIRT6, Biomarker, Ageing, Clinical trial, Arrivo, MDD, Pharmaceutical industry

Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.

Key Points: 
  • Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.
  • This registration-quality Phase 2b study will enroll 450 subjects with MDD and evaluate the effectiveness of SP-624, a SIRT6 activator and novel mechanism of action, compared to placebo in treating adults with Major Depressive Disorder.
  • The SP-624-202 study will assess the change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS) as its primary endpoint.
  • The MADRS is a 10-item depression rating scale commonly used to assess the severity of depression in clinical trials.

Green Circle Life Expands Availability of Healthy Weight for Life Program for the SmartFHR™ Platform

Retrieved on: 
Tuesday, April 16, 2024
Technology, Professional Services, Health, Pharmaceutical, Health Technology, Health Insurance, Data Analytics, Software, Fitness & Nutrition, Human Resources, Telemedicine, Virtual Medicine, Snack, ROI, Pharmacy, NCQA, AutoZone, HR, Eli Lilly, Insurance, Compensation, Partnership, Weight loss, Doctor of Philosophy, Quality assurance, Pharmacotherapy, Prescription, Obesity, Exercise, Life, Novo Nordisk, Diet, GCL, Workforce, National Committee, Quality of life

HWFL is an employer-offered weight management program designed to work with individuals to set realistic goals, attain and maintain their desired weight through lifestyle changes.

Key Points: 
  • HWFL is an employer-offered weight management program designed to work with individuals to set realistic goals, attain and maintain their desired weight through lifestyle changes.
  • The program, which provides private, personalized coaching, encourages users to engage in physical activities, nutritional adjustments and monitor weight outcomes.
  • Dinesh Sheth, founder and CEO of Green Circle Life, emphasized, “Health and wellness are at the forefront of HR challenges, and obesity is a national epidemic.
  • Healthy weight is not a 'one and done' 'one size fits all' proposition but rather a constantly evolving journey.

Ark Clinical Research Announces Advancing Accessibility for Obesity Through Innovative Research Trials on GLP-1 drugs

Retrieved on: 
Tuesday, April 16, 2024
Research, Fitness & Nutrition, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, General Health, Science, FDA, Organization, Diabetes, Learning, Hope, Statistics, Weight loss, Obesity, Exercise, Patient, Diet, Magnetic resonance, Ark, Pharmaceutical industry

Ark Clinical Research (“Ark”) is advancing accessible solutions for obesity and obesity-related diseases through clinical research and a free health clinic, which administers health assessments and manages patient care.

Key Points: 
  • Ark Clinical Research (“Ark”) is advancing accessible solutions for obesity and obesity-related diseases through clinical research and a free health clinic, which administers health assessments and manages patient care.
  • While the clinical research organization conducts Phase I-IV clinical trials in various therapeutic areas, the company is particularly focused on weight loss studies and accessibility of these drugs for those in need, particularly for low-income and minority patients.
  • While these studies are placebo controlled, they can provide another avenue for GLP-1 drugs or other obesity drugs.
  • If you are interested in learning more about Ark Clinical Research, please contact Samira Moran, CEO by phone at 310-710-2985 or by email at [email protected] .

AMRA Medical’s Innovative Fat Z-Score Biomarkers Show Tirzepatide Treatment is Associated with a Potential Targeted Effect on Visceral Fat and Liver Fat

Retrieved on: 
Wednesday, April 10, 2024
Biotechnology, Other Health, Diabetes, Health, General Health, Pharmaceutical, Health Technology, Other Science, Research, Surgery, Science, Disorder, T2D, Connective tissue, Bariatric surgery, Eli Lilly, Human, Weight, Tirzepatide, Metabolism, Obesity, Type 2 diabetes, Patient, Society, Magnetic resonance imaging, MRI, Multimedia, ASMBS, Medical imaging

For this reason, fat distribution profiling through personalized z-score assessment would represent an attractive and modifiable endpoint for future therapeutic efficacy trials in obesity and related disorders.

Key Points: 
  • For this reason, fat distribution profiling through personalized z-score assessment would represent an attractive and modifiable endpoint for future therapeutic efficacy trials in obesity and related disorders.
  • The personalized fat z-scores were introduced through research published in 2023 linking fat distribution patterns, as described by the z-scores, to specific cardiometabolic disease risk profiles in the general population.
  • The results showed that treatment with tirzepatide was associated with a significant reduction in visceral fat z-score (-0.18 SD) and liver fat z-score (-0.54 SD), while the subcutaneous fat z-score increased from an initially negative value (+0.11 SD) - suggesting a therapeutically-induced shift towards a better-balanced body fat distribution with prominent visceral and liver fat loss.
  • The significant reduction of visceral fat and liver fat z-scores observed with tirzepatide in SURPASS-3 MRI indicates a potential targeted effect beyond that expected by the magnitude of weight reduction.

Cedars-Sinai Launches Virtual Healthcare for Children and Spanish Speakers

Retrieved on: 
Wednesday, April 10, 2024
Software, General Health, Hispanic, Family, Telemedicine, Virtual Medicine, Consumer, Apps, Applications, Technology, Artificial Intelligence, Health Technology, Parenting, Children, Health, Pain, Language, AI, MD, Partnership, Cough, Parent, Depression, Obesity, Patient, Rash, Child, Anxiety, Connect, Nursing

Cedars-Sinai is expanding virtual healthcare for children and Spanish speakers in California through its mobile app Cedars-Sinai Connect , a fast-growing online option that allows patients to quickly access top healthcare professionals for acute, chronic and preventive care.

Key Points: 
  • Cedars-Sinai is expanding virtual healthcare for children and Spanish speakers in California through its mobile app Cedars-Sinai Connect , a fast-growing online option that allows patients to quickly access top healthcare professionals for acute, chronic and preventive care.
  • Parents of children 3 to 17 years old can now access Cedars-Sinai healthcare providers for urgent issues, including cough, cold, flu or rash.
  • Spanish-speaking healthcare providers are available for scheduled visits 7 a.m.-9 p.m. on weekdays and 8 a.m.-4 p.m. on weekends.
  • These patients also gain access to our broad network of specialists through referrals when appropriate.”
    The new care options for children and Spanish speakers build on Cedars-Sinai Connect’s initial success.

UnitedHealthcare Provides $180,000 Investment to United Disabilities Services Foundation to Support Aging and Disability Services in Pennsylvania

Retrieved on: 
Wednesday, April 10, 2024
Mental Health, People with Disabilities, Pets, Health Insurance, Other Health, Managed Care, Health, Consumer, General Health, Volunteering, Dog, Hospital, Spectrum, Disability, CDC, PTSD, Diabetes, Medicaid, Resource, Depression, Obesity, Exercise, Physician, Medicare, Adapted automobile, Ageing, UnitedHealth Group

UnitedHealthcare Community Plan of Pennsylvania has provided a $180,000 investment to the United Disabilities Services Foundation (UDSF) to support aging and disability services for adults across the state.

Key Points: 
  • UnitedHealthcare Community Plan of Pennsylvania has provided a $180,000 investment to the United Disabilities Services Foundation (UDSF) to support aging and disability services for adults across the state.
  • The nonprofit offers programs and resources to support people who are living with disabilities, aging or are recovering from an injury.
  • “UnitedHealthcare Community Plan of Pennsylvania is dedicated to helping people live healthier lives and is an organization that can be trusted to do what they say,” said William Kepner, CEO, United Disabilities Services Foundation.
  • They truly walk the talk and are great collaborative partners.”
    In Pennsylvania, 1 in 4 adults — nearly 26% — have a disability.

Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes

Retrieved on: 
Thursday, April 25, 2024
School, JMIR, University, University Challenge 2013–14, Prediabetes, Public health, Blood pressure, Dario, Overweight, BMI, Diabetes, Partnership, Empowerment, Research, A1C, Obesity, Blood, Type 2 diabetes, Medicine, Journal, Medical device

NEW YORK, April 25, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR) demonstrating a clinically significant reduction in blood glucose levels for members using Dario to manage weight alongside diabetes.

Key Points: 
  • Dario's cardiometabolic solution helps people manage related cardiometabolic health needs, including diabetes, pre-diabetes, blood pressure, weight and support for people taking a GLP-1, with a single integrated and highly personalized experience.
  • Dario's solution is designed to help people adopt the healthier behaviors required to support improved clinical outcomes, which includes self-health management behaviors such as monitoring weight and blood glucose.
  • This new retrospective, quasi-randomized study examined the data from 1,932 Dario members over the course of a year.
  • The research was conducted in partnership with Integrative Pain Laboratory, the School of Public Health at the University of Haifa.

First National Study to Assess the Prevalence of NAFLD to be Conducted by Federal Government

Retrieved on: 
Thursday, April 25, 2024
Congress, Fatty liver disease, ALF, Language, NAFLD, Liver disease, Risk, Hispanic, AHRQ, Overweight, Diabetes, FAST, Partnership, Agency, Research, American Liver Foundation, Disease, Obesity, Labour, NASH, Patient, Liver failure, Society, Metabolic syndrome, American Society of Transplantation, Liver transplantation, Prevalence, Dietary supplement

NEW YORK, April 25, 2024 /PRNewswire/ -- A first-ever national study to assess the prevalence of nonalcoholic fatty liver disease (NAFLD)* will be conducted by the Agency for Healthcare Research and Quality (AHRQ)**, in collaboration with other federal agency stakeholders, to evaluate the prevalence, diagnoses, treatments and complications associated with NAFLD.

Key Points: 
  • NEW YORK, April 25, 2024 /PRNewswire/ -- A first-ever national study to assess the prevalence of nonalcoholic fatty liver disease (NAFLD)* will be conducted by the Agency for Healthcare Research and Quality (AHRQ)**, in collaboration with other federal agency stakeholders, to evaluate the prevalence, diagnoses, treatments and complications associated with NAFLD.
  • New national study to assess prevalence of NAFLD to be conducted, ALF grateful to Congress and advocates.
  • "We are so grateful to Senator Bill Cassidy (R-LA) for his leadership in championing this effort on Capitol Hill.
  • In an online liver health quiz to assess risk factors, 93% of respondents received a positive result for being at risk for NAFLD.

FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease

Retrieved on: 
Thursday, April 25, 2024
Leg, FDA, Cancer, Hip, Medivir, Sequela, Priority review, Risk, Osteoclast, Osteoarthritis, Partnership, Depression, Disease, Obesity, Patient, Cathepsin K, ODD, Ageing, Pharmaceutical industry

The FDA defines a rare pediatric disease as a serious or life-threatening disease in which the disease manifestations primarily affect individuals aged from birth to 18 years of age.

Key Points: 
  • The FDA defines a rare pediatric disease as a serious or life-threatening disease in which the disease manifestations primarily affect individuals aged from birth to 18 years of age.
  • Pediatric diseases recognized as "rare", affect fewer than 200,000 people in the United States.
  • We are delighted that MIV-711 has been granted RPDD by the FDA with the potential to become the first approved treatment option.
  • To gain RPDD, there must be supportive data suggesting that the drug may be effective in the disease.